AstraZeneca Settles Toprol Antitrust Action For $20M

Law360, New York (September 26, 2011, 8:57 PM EDT) -- AstraZeneca Pharmaceuticals LP on Monday agreed to pay $20 million to settle claims brought in Delaware by a putative class of direct purchasers of Toprol-XL who allege the pharmaceutical giant used sham patent litigation to delay generic competition for the hypertension drug.

The plaintiffs asserted that beginning in May 2005 the drug company used fraudulently obtained patents and sham patent infringement suits to impede the approval and market entry of generic metoprolol succinate, which it markets under the brand name Toprol-XL.

The direct purchaser plaintiffs, including...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.